Login to Your Account



Is it a 3 Musketeers Scenario?

Will Contrave Vote Bode Well for All Obesity Drugmakers?

By Donna Young


Thursday, December 9, 2010
WASHINGTON – Investors in Orexigen Therapeutics Inc. Wednesday were not only bubbling over with excitement about an FDA panel's backing of the firm's obesity drug Contrave (naltrexone/bupropion) – with the company's stock rocketing as high as 129 percent – but shares of potential competitors Arena Pharmaceuticals Inc. and Vivus Inc. also were on fire, leaping as high as 20.5 percent and 19.5 percent, respectively.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription